PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Second Universal Definition of Heart Failure abandons rigid ejection fraction cutoffs

heart failureHFrEFHFpEFHFimpEFleft ventricular ejection fractionuniversal definitionconsensus documentcardiomyopathy classificationSGLT2 inhibitorsGLP-1 receptor agonistsfinerenonenatriuretic peptidescardiac amyloidosisguideline Guideline: Heart Failure

Background Information

A new universal definition reshapes heart failure management globally.

Heart failure (HF) is increasingly prevalent, affecting global health. Standardizing its definition can improve research, prevention, and management. The document proposes a universal definition and classification for HF, moving beyond rigid ejection fraction cutoffs to a more comprehensive framework. By adopting a unified approach, clinicians can better diagnose, manage, and prevent HF, considering both clinical and social determinants of health. A new standardized definition framework aims to improve HF global management and outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, Bozkurt B, Cikes M, Damasceno A, Desai AS, Felker GM, Hogan G, Kinugawa K, Kittleson M, Lam CSP, Mcdonagh T, Metra M, Mullens W, Ribeiro ALP, Vaughn Y, Vest A, Joint American Heart Association (AHA)/American College of Cardiology (ACC)/European Society of Cardiology (ESC)/World Heart Federation (WHF) Task Force for the Universal Definition of Heart Failure in collaboration with the Heart Failure Society of America (HFSA), the Heart Failure Association (HFA) of the European Society of Cardiology, and the Japanese Heart Failure Society (JHFS)

Citation: Walsh MN, Kober L, Sliwa K, et al. AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026). Global heart. 2026;21(1):51. doi:10.5334/gh.1569

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →